{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brexpiprazole", "query": { "intervention": "brexpiprazole" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 57, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brexpiprazole&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T20:27:57.153Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04124614", "title": "Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post Traumatic Stress Disorder" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 450, "start_date": "2019-10-17", "completion_date": "2023-08-08", "has_results": true, "last_update_posted_date": "2025-06-13", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04124614" }, { "nct_id": "NCT03526354", "title": "Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Substance Use Disorders" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Treatment as Usual", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Massachusetts, Worcester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2018-06-19", "completion_date": "2024-02-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 4, "location_summary": "Augusta, Georgia • Boston, Massachusetts • Worcester, Massachusetts + 1 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03526354" }, { "nct_id": "NCT01074294", "title": "Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "OPDC-34712", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Stimulant Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 740, "start_date": "2010-03-16", "completion_date": "2011-06-20", "has_results": true, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 35, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074294" }, { "nct_id": "NCT03548584", "title": "A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Agitation Associated With Alzheimer's Dementia", "Alzheimer Dementia" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 345, "start_date": "2018-05-16", "completion_date": "2022-06-01", "has_results": true, "last_update_posted_date": "2023-09-18", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03548584" }, { "nct_id": "NCT01360866", "title": "Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder", "Depression", "Depressive Disorder, Major", "Mood Disorders", "Mental Disorders" ], "interventions": [ { "name": "OPC-34712", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Paroxetine CR", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Venlafaxine XR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2944, "start_date": "2011-10", "completion_date": "2017-05-18", "has_results": true, "last_update_posted_date": "2018-09-17", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 93, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01360866" }, { "nct_id": "NCT01727726", "title": "A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder", "Depression", "Depressive Disorder, Major", "Mood Disorders", "Mental Disorders" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Seroquel XR", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 2182, "start_date": "2012-12", "completion_date": "2016-11-10", "has_results": true, "last_update_posted_date": "2018-06-08", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01727726" }, { "nct_id": "NCT00797966", "title": "Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "OPC-34712", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "ADT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 850, "start_date": "2009-05", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2016-02-29", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 50, "location_summary": "Arcadia, California • Beverly Hills, California • Escondido, California + 43 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00797966" }, { "nct_id": "NCT01987960", "title": "Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post-traumatic Stress Disorder", "PTSD" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Brexpiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 417, "start_date": "2013-12", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 22, "location_summary": "Los Angeles, California • Riverside, California • San Diego, California + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01987960" }, { "nct_id": "NCT02192554", "title": "Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Agitation Associated With Alzheimer's Disease", "Alzheimer's Type", "Mental Disorder", "Nervous System Diseases" ], "interventions": [], "intervention_types": [], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 450, "start_date": "2014-06", "completion_date": "2017-05", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 28, "location_summary": "Tuscaloosa, Alabama • Costa Mesa, California • Lakewood, California + 21 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Lakewood", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192554" }, { "nct_id": "NCT02411695", "title": "Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Brexpiprazole (OPC-34712)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "13 Years to 17 Years" }, "enrollment_count": 43, "start_date": "2015-03", "completion_date": "2017-01-01", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-09-02T20:27:57.153Z", "location_count": 10, "location_summary": "Little Rock, Arkansas • Culver City, California • Orange, California + 7 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02411695" } ] }